{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:34:30Z","timestamp":1790116470840,"version":"4.0.1"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","thrombosisresearch.com","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.thromres.2024.04.005","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T02:10:17Z","timestamp":1712715017000},"page":"171-180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Is there a role for the laboratory monitoring in the management of specific antidotes of direct oral anticoagulants?"],"prefix":"10.1016","volume":"237","author":[{"given":"Nicolas","family":"Gendron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Billoir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Siguret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Le Cam-Duchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Proulle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Macchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Boissier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Mouton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"De Maistre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Gouin-Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Jourdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.thromres.2024.04.005_bb0005","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-018180","article-title":"Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French health insurance databases","volume":"8","author":"Huiart","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.thromres.2024.04.005_bb0010","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/7636104","article-title":"An update on the reversal of non-vitamin K antagonist Oral anticoagulants","author":"Mujer","year":"2020","journal-title":"Adv Hematol"},{"issue":"9921","key":"10.1016\/j.thromres.2024.04.005_bb0015","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.thromres.2024.04.005_bb0020","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2024.04.005_bb0025","doi-asserted-by":"crossref","unstructured":"Yoshida R de A, Yoshida WB, Maffei FH de A, El Dib R, Nunes R, Rollo HA. Systematic review of randomized controlled trials of new anticoagulants for venous thromboembolism prophylaxis in major orthopedic surgeries, compared with enoxaparin. Ann. Vasc. Surg. 2013;27(3):355\u2013369.","DOI":"10.1016\/j.avsg.2012.06.010"},{"issue":"20","key":"10.1016\/j.thromres.2024.04.005_bb0030","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa1913808","article-title":"Rivaroxaban or enoxaparin in nonmajor orthopedic surgery","volume":"382","author":"Samama","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10117","key":"10.1016\/j.thromres.2024.04.005_bb0035","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Anand","year":"2018","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.thromres.2024.04.005_bb0040","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1182\/blood-2018-04-791541","article-title":"Testing and monitoring direct oral anticoagulants","volume":"132","author":"Connors","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.thromres.2024.04.005_bb0045","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1055\/s-0038-1627480","article-title":"International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct Oral anticoagulants","volume":"118","author":"Gosselin","year":"2018","journal-title":"Thromb. Haemost."},{"issue":"8","key":"10.1016\/j.thromres.2024.04.005_bb0050","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1055\/a-1450-8178","article-title":"2021 update of the International Council for Standardization in Haematology recommendations for laboratory measurement of direct Oral anticoagulants","volume":"121","author":"Douxfils","year":"2021","journal-title":"Thromb. Haemost."},{"issue":"31","key":"10.1016\/j.thromres.2024.04.005_bb0055","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1093\/eurheartj\/ehx403","article-title":"Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study","volume":"38","author":"Godier","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2024.04.005_bb0060","unstructured":"Smadja D-M, Gendron N, Sanchez O, groupe de travail Recommandations de bonne pratique pour la prise en charge de la MVTE. [Who should supervise anticoagulant treatment and how?]. Rev. Mal. Respir. (Epub ahead of print)."},{"issue":"1","key":"10.1016\/j.thromres.2024.04.005_bb0065","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.chest.2016.08.1462","article-title":"Laboratory assessment of the anticoagulant activity of direct Oral anticoagulants: A systematic review","volume":"151","author":"Samuelson","year":"2017","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.thromres.2024.04.005_bb0070","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.chest.2017.09.047","article-title":"Are screening tests reliable to rule out direct Oral anticoagulant plasma levels at various thresholds (30, 50, or 100 ng\/mL) in emergency situations?","volume":"153","author":"Jabet","year":"2018","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.thromres.2024.04.005_bb0075","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5853\/jos.2022.03034","article-title":"Practical nomogram predicting Apixaban or rivaroxaban concentrations from low-molecular-weight heparin anti-Xa values: special interest in acute ischemic stroke patients","volume":"25","author":"Brakta","year":"2023","journal-title":"J Stroke"},{"issue":"3","key":"10.1016\/j.thromres.2024.04.005_bb0080","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1213\/ANE.0000000000005114","article-title":"Heparin anti-Xa activity, a readily available unique test to quantify Apixaban, rivaroxaban, Fondaparinux, and Danaparoid levels","volume":"132","author":"Boissier","year":"2021","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.thromres.2024.04.005_bb0085","first-page":"2151","article-title":"Low molecular weight heparin anti-Xa assays can identify patients with clinically important apixaban and rivaroxaban drug levels","author":"Mithoowani","year":"2022","journal-title":"Thromb. Res."},{"issue":"4","key":"10.1016\/j.thromres.2024.04.005_bb0090","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/1060028018811657","article-title":"Anti-Xa Oral anticoagulant plasma concentration assay in real life: rivaroxaban and Apixaban quantification in emergency with LMWH calibrator","volume":"53","author":"Billoir","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.thromres.2024.04.005_bb0095","first-page":"158126","article-title":"Evaluation of dabigatran, rivaroxaban and apixaban target-specific assays in a multicenter French study","author":"Gouin-Thibault","year":"2017","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2024.04.005_bb0100","article-title":"Comparison of the DOAC dipstick test on urine samples with chromogenic substrate methods on plasma samples in outpatients treated with direct Oral anticoagulants","volume":"2910760296231179684","author":"Papageorgiou","year":"2023","journal-title":"Clin. Appl. Thromb. Hemost."},{"issue":"4","key":"10.1016\/j.thromres.2024.04.005_bb0105","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1161\/STROKEAHA.122.041555","article-title":"Assessment of direct Oral anticoagulant status using the DOASENSE dipstick in thrombolysis eligible patients with stroke: proof-of-concept study","volume":"54","author":"Tan","year":"2023","journal-title":"Stroke"},{"issue":"11","key":"10.1016\/j.thromres.2024.04.005_bb0110","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1111\/jth.13139","article-title":"Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Chai-Adisaksopha","year":"2015","journal-title":"J. Thromb. Haemost."},{"issue":"10","key":"10.1016\/j.thromres.2024.04.005_bb0115","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.7326\/M21-1094","article-title":"Long-term risk for major bleeding during extended Oral anticoagulant therapy for first unprovoked venous thromboembolism","volume":"174","author":"Khan","year":"2021","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"10.1016\/j.thromres.2024.04.005_bb0120","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.25475","article-title":"Reversal of direct oral anticoagulants: guidance from the anticoagulation forum","volume":"94","author":"Cuker","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/j.thromres.2024.04.005_bb0125","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"issue":"7","key":"10.1016\/j.thromres.2024.04.005_bb0130","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s11739-018-1877-z","article-title":"Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-event registry","volume":"13","author":"Testa","year":"2018","journal-title":"Intern. Emerg. Med."},{"issue":"4","key":"10.1016\/j.thromres.2024.04.005_bb0135","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.accpm.2018.04.009","article-title":"Management of bleeding and emergency invasive procedures in patients on dabigatran: updated guidelines from the French working group on perioperative Haemostasis (GIHP) - September 2016","volume":"37","author":"Albaladejo","year":"2018","journal-title":"Anaesth Crit Care Pain Med"},{"issue":"3","key":"10.1016\/j.thromres.2024.04.005_bb0140","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/jth.13227","article-title":"When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH","volume":"14","author":"Levy","year":"2016","journal-title":"J. Thromb. Haemost."},{"issue":"18","key":"10.1016\/j.thromres.2024.04.005_bb0145","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1161\/CIRCULATIONAHA.113.005754","volume":"129","author":"Sherwood","year":"2014","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.thromres.2024.04.005_bb0150","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur. Heart J."},{"issue":"15","key":"10.1016\/j.thromres.2024.04.005_bb0155","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1182\/bloodadvances.2020002335","article-title":"Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure","volume":"4","author":"Shaw","year":"2020","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.thromres.2024.04.005_bb0160","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/ene.13582","article-title":"Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants","volume":"25","author":"Touz\u00e9","year":"2018","journal-title":"Eur. J. Neurol."},{"issue":"18","key":"10.1016\/j.thromres.2024.04.005_bb0165","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2012-11-468207","article-title":"A specific antidote for dabigatran: functional and structural characterization","volume":"121","author":"Schiele","year":"2013","journal-title":"Blood"},{"issue":"9994","key":"10.1016\/j.thromres.2024.04.005_bb0170","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0140-6736(15)60732-2","article-title":"Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial","volume":"386","author":"Glund","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.thromres.2024.04.005_bb0175","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1177\/1076029618755947","article-title":"The renal elimination pathways of the dabigatran reversal agent Idarucizumab and its impact on dabigatran elimination","volume":"24","author":"Glund","year":"2018","journal-title":"Clin. Appl. Thromb. Hemost."},{"issue":"12","key":"10.1016\/j.thromres.2024.04.005_bb0180","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.thromres.2024.04.005_bb0185","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","article-title":"The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY trial (randomized evaluation of long-term anticoagulation therapy)","volume":"63","author":"Reilly","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.thromres.2024.04.005_bb0190","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1160\/TH16-05-0385","article-title":"Idarucizumab does not have procoagulant effects: assessment of thrombosis biomarkers in healthy volunteers","volume":"117","author":"Schmohl","year":"2017","journal-title":"Thromb. Haemost."},{"issue":"13","key":"10.1016\/j.thromres.2024.04.005_bb0195","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.jacc.2016.01.043","article-title":"Restarting dabigatran Etexilate 24 h after reversal with Idarucizumab and Redosing Idarucizumab in healthy volunteers","volume":"67","author":"Glund","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.thromres.2024.04.005_bb0200","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/rth2.12029","article-title":"Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study","volume":"1","author":"Yasaka","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"issue":"6","key":"10.1016\/j.thromres.2024.04.005_bb0205","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for Dabigatran Reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.thromres.2024.04.005_bb0210","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal - full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.thromres.2024.04.005_bb0215","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40119-020-00165-8","article-title":"Idarucizumab for emergency reversal of anticoagulant effects of dabigatran: interim results of a Japanese post-marketing surveillance study","volume":"9","author":"Yasaka","year":"2020","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.thromres.2024.04.005_bb0220","article-title":"Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany-updated series of 120 cases","volume":"1747493019895654","author":"Kermer","year":"2020","journal-title":"Int. J. Stroke"},{"key":"10.1016\/j.thromres.2024.04.005_bb0225","doi-asserted-by":"crossref","unstructured":"Jin C, Huang RJ, Peterson ED, et al. Intravenous tPA (tissue-type plasminogen activator) in patients with acute ischemic stroke taking non-vitamin K antagonist Oral anticoagulants preceding stroke. Stroke 2018;49(9):2237\u20132240.","DOI":"10.1161\/STROKEAHA.118.022128"},{"issue":"1","key":"10.1016\/j.thromres.2024.04.005_bb0230","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ejhf.1356","article-title":"Idarucizumab for the reversal of dabigatran in patients undergoing heart transplantation","volume":"21","author":"Keer","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.thromres.2024.04.005_bb0235","doi-asserted-by":"crossref","unstructured":"Kalmanovich E, Gaudard P, Roubille F. Letter on \u201cIdarucizumab for the reversal of dabigatran in patients undergoing heart transplantation.\u201d Eur. J. Heart Fail. 2019;21(6):818.","DOI":"10.1002\/ejhf.1446"},{"key":"10.1016\/j.thromres.2024.04.005_bb0240","doi-asserted-by":"crossref","unstructured":"Crespo-Leiro MG, L\u00f3pez-Vilella R, L\u00f3pez Granados A, et al. Use of Idarucizumab to reverse the anticoagulant effect of dabigatran in cardiac transplant surgery. A multicentric experience in Spain. Clin Transplant;33(12):.","DOI":"10.1111\/ctr.13748"},{"issue":"2","key":"10.1016\/j.thromres.2024.04.005_bb0245","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s40256-019-00360-6","article-title":"Real world outcomes associated with Idarucizumab: population-based retrospective cohort study","volume":"20","author":"Singh","year":"2020","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.thromres.2024.04.005_bb0250","first-page":"22821","article-title":"Idarucizumab for dabigatran reversal: A systematic review and meta-analysis of indications and outcomes","author":"van der Horst","year":"2023","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2024.04.005_bb0255","doi-asserted-by":"crossref","unstructured":"van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb. Haemost. 2010;103(6):1116\u20131127.","DOI":"10.1160\/TH09-11-0758"},{"key":"10.1016\/j.thromres.2024.04.005_bb0260","unstructured":"de Fautereau-Vassel A, Mokhtarian A, Mangenot M, et al. Comparisons between diluted thrombin time, ecarin chromogenic assays, and UPLC-MS for plasma level dabigatran quantification: results from DRIVING study. Int. J. Lab. Hematol. (Epub ahead of print)."},{"issue":"7","key":"10.1016\/j.thromres.2024.04.005_bb0265","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/jth.13706","article-title":"The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran","volume":"15","author":"Simon","year":"2017","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.thromres.2024.04.005_bb0270","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.3324\/haematol.2017.183400","article-title":"Usefulness of initial plasma dabigatran concentration to predict rebound after reversal","volume":"103","author":"Gendron","year":"2018","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.thromres.2024.04.005_bb0275","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/europace\/euy220","article-title":"Performance of idarucizumab as antidote of dabigatran in daily clinical practice","volume":"21","author":"van der Wall","year":"2019","journal-title":"Europace"},{"issue":"9994","key":"10.1016\/j.thromres.2024.04.005_bb0280","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0140-6736(15)60732-2","article-title":"Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial","volume":"386","author":"Glund","year":"2015","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.thromres.2024.04.005_bb0285","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1161\/CIRCULATIONAHA.115.019628","article-title":"Idarucizumab","volume":"132","author":"Eikelboom","year":"2015","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.thromres.2024.04.005_bb0290","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.jacc.2019.07.070","article-title":"Dabigatran reversal with Idarucizumab in patients with renal impairment","volume":"74","author":"Eikelboom","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2024.04.005_bb0295","article-title":"Dabigatran level before reversal can predict hemostatic effectiveness of Idarucizumab in a real-world setting","volume":"7599626","author":"Gendron","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.thromres.2024.04.005_bb0300","doi-asserted-by":"crossref","unstructured":"Glund S, Stangier J, Ryn J van, et al. Effect of age and renal function on Idarucizumab pharmacokinetics and Idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, Crossover Phase Ib Study. Clin Pharmacokinet 2017;56(1):41\u201354.","DOI":"10.1007\/s40262-016-0417-0"},{"issue":"5","key":"10.1016\/j.thromres.2024.04.005_bb0305","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal - full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.thromres.2024.04.005_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100201","article-title":"Dabigatran-reversal failure using standard dose of idarucizumab: a systematic review and meta-analysis of cases","volume":"7","author":"Melicine","year":"2023","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"8","key":"10.1016\/j.thromres.2024.04.005_bb0315","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/15563650.2020.1743846","article-title":"Incomplete responses to the recommended dose of idarucizumab: a systematic review and pharmacokinetic analysis","volume":"58","author":"Athavale","year":"2020","journal-title":"Clin. Toxicol. (Phila.)"},{"key":"10.1016\/j.thromres.2024.04.005_bb0320","first-page":"197179","article-title":"Real-world experience with reversal of dabigatran by idarucizumab","author":"Haastrup","year":"2021","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2024.04.005_bb0325","unstructured":"Levy JH, van Ryn J, Sellke FW, et al. Dabigatran reversal with Idarucizumab in patients requiring urgent surgery: A subanalysis of the RE-VERSE AD study. Ann. Surg. (Epub ahead of print)."},{"issue":"3","key":"10.1016\/j.thromres.2024.04.005_bb0330","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jjcc.2022.04.007","article-title":"Treatment strategy of dabigatran etexilate following the availability of idarucizumab in Japanese patients with non-valvular atrial fibrillation: J-dabigatran surveillance 2","volume":"80","author":"Yamashita","year":"2022","journal-title":"J. Cardiol."},{"issue":"7","key":"10.1016\/j.thromres.2024.04.005_bb0335","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1055\/a-1704-0630","article-title":"Retrospective analysis of the effectiveness of a reduced dose of Idarucizumab in dabigatran reversal","volume":"122","author":"Stone","year":"2022","journal-title":"Thromb. Haemost."},{"issue":"10","key":"10.1016\/j.thromres.2024.04.005_bb0340","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1053\/j.jvca.2021.02.029","article-title":"Appropriate use of Idarucizumab for dabigatran reversal according to the international society on thrombosis and hemostasis and French working group on perioperative hemostasis: A French retrospective study","volume":"35","author":"Gendron","year":"2021","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"issue":"18","key":"10.1016\/j.thromres.2024.04.005_bb0345","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1161\/CIRCULATIONAHA.119.041687","article-title":"Specific antidotes for direct Oral anticoagulant reversal: Case closed or cold Case?","volume":"140","author":"Godier","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.thromres.2024.04.005_bb0350","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-0039-1695771","article-title":"Global use of Idarucizumab in clinical practice: outcomes of the RE-VECTO surveillance program","volume":"120","author":"Fanikos","year":"2020","journal-title":"Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2024.04.005_bb0355","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.3102","article-title":"A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa","volume":"19","author":"Lu","year":"2013","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.thromres.2024.04.005_bb0360","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/bloodadvances.2019000885","article-title":"A phase 2 PK\/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers","volume":"4","author":"Lu","year":"2020","journal-title":"Blood Adv."},{"issue":"21","key":"10.1016\/j.thromres.2024.04.005_bb0365","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/bloodadvances.2017007112","article-title":"Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa","volume":"1","author":"Siegal","year":"2017","journal-title":"Blood Adv."},{"issue":"16","key":"10.1016\/j.thromres.2024.04.005_bb0370","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1182\/bloodadvances.2016003616","article-title":"Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors","volume":"2","author":"Kalathottukaren","year":"2018","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.thromres.2024.04.005_bb0375","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1160\/TH14-10-0877","article-title":"Association rate constants rationalise the pharmacodynamics of apixaban and rivaroxaban","volume":"114","author":"Jourdi","year":"2015","journal-title":"Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2024.04.005_bb0380","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11239-019-01973-z","article-title":"Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage","volume":"49","author":"Frontera","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"issue":"4","key":"10.1016\/j.thromres.2024.04.005_bb0385","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1161\/STROKEAHA.120.031108","article-title":"Economic evaluation of Andexanet versus prothrombin complex concentrate for reversal of factor Xa-associated intracranial hemorrhage","volume":"52","author":"Micieli","year":"2021","journal-title":"Stroke"},{"issue":"14","key":"10.1016\/j.thromres.2024.04.005_bb0390","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of Andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.thromres.2024.04.005_bb0395","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1161\/CIRCULATIONAHA.121.057844","article-title":"Final study report of Andexanet alfa for major bleeding with factor Xa inhibitors","volume":"147","author":"Milling","year":"2023","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.thromres.2024.04.005_bb0400","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1161\/STROKEAHA.120.030565","article-title":"Hemostatic efficacy and anti-FXa (factor Xa) reversal with Andexanet alfa in intracranial hemorrhage: ANNEXA-4 substudy","volume":"52","author":"Demchuk","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.thromres.2024.04.005_bb0405","first-page":"45627","article-title":"Real world utilization of Andexanet alfa at a community hospital","author":"Santarelli","year":"2021","journal-title":"Am. J. Emerg. Med."},{"issue":"1","key":"10.1016\/j.thromres.2024.04.005_bb0410","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2217\/fca-2020-0073","article-title":"Real-world management of oral factor Xa inhibitor-related bleeds with reversal or replacement agents including andexanet alfa and four-factor prothrombin complex concentrate: a multicenter study","volume":"17","author":"Coleman","year":"2021","journal-title":"Future Cardiol."},{"issue":"10","key":"10.1016\/j.thromres.2024.04.005_bb0415","doi-asserted-by":"crossref","first-page":"E278","DOI":"10.1002\/ajh.25587","article-title":"Coordinating emergent procedures after andexanet alfa","volume":"94","author":"Culbreth","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.thromres.2024.04.005_bb0420","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ajem.2019.12.008","article-title":"Real-world utilization of andexanet alfa","volume":"38","author":"Brown","year":"2020","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.thromres.2024.04.005_bb0425","article-title":"Coagulation factor Xa (recombinant), inactivated-Zhzo (Andexanet alfa) hemostatic outcomes and thrombotic event incidence at an Academic Medical Center","volume":"251076029619896619","author":"Stevens","year":"2019","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2024.04.005_bb0430","article-title":"Retrospective comparison of Andexanet alfa and 4-factor prothrombin complex for reversal of factor Xa-inhibitor related bleeding","volume":"2710760296211039020","author":"Stevens","year":"2021","journal-title":"Clin. Appl. Thromb. Hemost."},{"issue":"7","key":"10.1016\/j.thromres.2024.04.005_bb0435","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1111\/jth.14838","article-title":"Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages","volume":"18","author":"Barra","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.04.005_bb0440","article-title":"An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage","volume":"195106070","author":"Giovino","year":"2020","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"1","key":"10.1016\/j.thromres.2024.04.005_bb0445","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12028-020-01161-5","article-title":"Andexanet alfa versus 4-factor prothrombin complex concentrate for reversal of factor Xa inhibitors in intracranial hemorrhage","volume":"35","author":"Ammar","year":"2021","journal-title":"Neurocrit. Care"},{"issue":"4","key":"10.1016\/j.thromres.2024.04.005_bb0450","doi-asserted-by":"crossref","DOI":"10.1097\/CCE.0000000000000356","article-title":"Real-world observational review of Andexanet alfa prescribing and utilization outcomes at a community teaching hospital","volume":"3","author":"Sobolewski","year":"2021","journal-title":"Crit Care Explor"},{"issue":"6","key":"10.1016\/j.thromres.2024.04.005_bb0455","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1055\/s-0041-1740180","article-title":"Andexanet alfa for specific anticoagulation reversal in patients with acute bleeding during treatment with edoxaban","volume":"122","author":"Benz","year":"2022","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.04.005_bb0460","first-page":"5538","article-title":"Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages","author":"Pham","year":"2022","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.thromres.2024.04.005_bb0465","first-page":"5516","article-title":"Andexanet alfa effectiveness and safety versus four-factor prothrombin complex concentrate (4F-PCC) in intracranial hemorrhage while on apixaban or rivaroxaban: A single-center, retrospective, matched cohort analysis","author":"Parsels","year":"2022","journal-title":"Am. J. Emerg. Med."},{"issue":"5","key":"10.1016\/j.thromres.2024.04.005_bb0470","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/MBC.0000000000001128","article-title":"Reversal of factor Xa inhibitors associated intracranial haemorrhage at a tertiary medical Centre","volume":"33","author":"Milioglou","year":"2022","journal-title":"Blood Coagul. Fibrinolysis"},{"issue":"1","key":"10.1016\/j.thromres.2024.04.005_bb0475","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11239-021-02495-3","article-title":"Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage","volume":"53","author":"Vestal","year":"2022","journal-title":"J. Thromb. Thrombolysis"},{"issue":"6","key":"10.1016\/j.thromres.2024.04.005_bb0480","article-title":"Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study. Res Pract","volume":"7","author":"Dobesh","year":"2023","journal-title":"Thromb. Haemost."},{"issue":"25","key":"10.1016\/j.thromres.2024.04.005_bb0485","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","article-title":"Andexanet alfa for the reversal of factor Xa inhibitor activity","volume":"373","author":"Siegal","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.thromres.2024.04.005_bb0490","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","article-title":"Andexanet alfa for acute major bleeding associated with factor Xa inhibitors","volume":"375","author":"Connolly","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.thromres.2024.04.005_bb0495","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12775","article-title":"In vitro reversal of direct factor Xa inhibitors: direct comparison of andexanet alfa and prothrombin complex concentrates Cofact and Beriplex\/Kcentra","volume":"6","author":"Brinkman","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.thromres.2024.04.005_bb0500","article-title":"Modified anti-FXa assays for measuring the residual activity of Apixaban and rivaroxaban in Andexanet alfa-containing samples on the ACL TOP family\u00ae coagulation analyzers","volume":"134(Supplement_1):1153","author":"Khan","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.thromres.2024.04.005_bb0505","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/ijlh.13591","article-title":"Measuring residual anti-Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa","volume":"43","author":"Bourdin","year":"2021","journal-title":"Int. J. Lab. Hematol."},{"issue":"Supplement 1","key":"10.1016\/j.thromres.2024.04.005_bb0510","first-page":"5","article-title":"Analytical performance of modified anti-FXa assays for Andexanet alfa-containing plasma samples on the ACL TOP\/TOP 50 coagulation analyzers","volume":"136","author":"Khan","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2024.04.005_bb0515","article-title":"Reversal of factor Xa inhibitors by Andexanet alfa may increase Thrombogenesis compared to pretreatment values","volume":"251076029619863493","author":"Siddiqui","year":"2019","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2024.04.005_bb0520","unstructured":"ANNEXA-I: Andexanet Alfa Shows Efficacy, Safety for Factor Xa Reversal in Acute ICH. AJMC. https:\/\/www.ajmc.com\/view\/annexa-i-andexanet-alfa-shows-efficacy-safety-for-factor-xa-reversal-in-acute-ich (2023, accessed February 16, 2024)."},{"issue":"16","key":"10.1016\/j.thromres.2024.04.005_bb0525","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1182\/bloodadvances.2016003616","article-title":"Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors","volume":"2","author":"Kalathottukaren","year":"2018","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.thromres.2024.04.005_bb0530","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1053\/j.jvca.2020.10.042","article-title":"Successful Antithrombin Administration in Andexanet Alfa-Associated Heparin Resistance","volume":"35","author":"Apostel","year":"2021","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"issue":"8","key":"10.1016\/j.thromres.2024.04.005_bb0535","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/phar.2306","article-title":"Intraoperative unfractionated heparin unresponsiveness during endovascular repair of a ruptured abdominal aortic aneurysm following Administration of Andexanet Alfa for the reversal of rivaroxaban","volume":"39","author":"Eche","year":"2019","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.thromres.2024.04.005_bb0540","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40981-023-00619-7","article-title":"Successful use of an antithrombin for heparin resistance with andexanet alfa","volume":"9","author":"Honda","year":"2023","journal-title":"JA Clin Rep"},{"issue":"4","key":"10.1016\/j.thromres.2024.04.005_bb0545","doi-asserted-by":"crossref","first-page":"390","DOI":"10.5811\/cpcem.2019.9.43650","article-title":"Difficult intraoperative Heparinization following Andexanet alfa administration","volume":"3","author":"Watson","year":"2019","journal-title":"Clin Pract Cases Emerg Med"},{"key":"10.1016\/j.thromres.2024.04.005_bb0550","unstructured":"Abstract 18218: In Vitro Characterization of Andexanet Alfa (PRT064445), a Specific fXa Inhibitor Antidote versus Aripazine (PER977), a Non-specific Reversal Agent | Circulation. https:\/\/www.ahajournals.org\/doi\/10.1161\/circ.130.suppl_2.18218 (accessed July 18, 2023)."},{"issue":"2","key":"10.1016\/j.thromres.2024.04.005_bb0555","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1160\/TH16-03-0224","article-title":"Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban","volume":"117","author":"Ansell","year":"2017","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.04.005_bb0560","unstructured":"Ansell JE, Laulicht BE, Bakhru SH, Hoffman M, Steiner SS, Costin JC. Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin. Thromb. Res. (Epub ahead of print)."},{"issue":"10","key":"10.1016\/j.thromres.2024.04.005_bb0565","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/eurheartj\/ehab637","article-title":"Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects","volume":"43","author":"Ansell","year":"2022","journal-title":"Eur. Heart J."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004938482400118X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004938482400118X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T05:21:28Z","timestamp":1714108888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004938482400118X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":113,"alternative-id":["S004938482400118X"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2024.04.005","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is there a role for the laboratory monitoring in the management of specific antidotes of direct oral anticoagulants?","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2024.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}